Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo.
Shingo NakamuraNaoko AndoMasayuki IshiharaMasahiro SatoPublished in: Nanomaterials (Basel, Switzerland) (2020)
We previously reported that heparin/protamine particles (LHPPs) produced as nanoparticles through simple mixing of raw materials exhibit sustained protein release and can be retained in cells. In the present study, we modified LHPPs without employing any organic synthetic approach. The resulting LHPPs were re-named as improved LHPPs (i-LHPPs) and have the ability to retain cell-penetrating peptides (GRKKRRQRRRPPQ) based on electrostatic interactions. We examined whether i-LHPPs can introduce exogenous proteins (i.e., lacZ protein encoding bacterial β-galactosidase) into cultured cells in vitro, or into murine hepatocytes in vivo through intravenous injection to anesthetized mice. We found an accumulation of the transferred protein in both in vitro cultured cells and in vivo hepatocytes. To the best of our knowledge, reports of successful in vivo delivery to hepatocytes are rare. The i-LHPP-based protein delivery technique will be useful for in vivo functional genetic modification of mouse hepatocytes using Cas9 protein-mediated genome editing targeting specific genes, leading to the creation of hepatic disease animal models for research that aims to treat liver diseases.
Keyphrases
- induced apoptosis
- genome editing
- crispr cas
- protein protein
- amino acid
- cell cycle arrest
- binding protein
- endothelial cells
- liver injury
- emergency department
- endoplasmic reticulum stress
- high dose
- signaling pathway
- oxidative stress
- gene expression
- drug delivery
- dna methylation
- metabolic syndrome
- small molecule
- adipose tissue
- bone marrow
- single cell
- low dose
- adverse drug
- transcription factor